Five things for pharma marketers to know: Tuesday, September 2

September 2, 2014 4:43 PM

2 0

Five things for pharma marketers to know: Tuesday, September 2

Sanofi and Regeneron offered results of their Phase-III trials for LDL-cholesterol lowering treatment and PCSK9 antibody, alirocumab, at the European Society of Cardiology Congress in Barcelona over the weekend. At 24 weeks of treatment, patients with hypercholesterolemia—as well as those with the genetic disorder heterozygous familial hypercholesterolemia (HeFH)—observed a 61% reduction from baseline LDL cholesterol levels. Eighty-one percent of patients achieved their LDL cholesterol goal, the drugmakers reported. All four reported trials met their primary efficacy endpoint. Sanofi/Regeneron plan to submit the drug to US and EU regulatory authorities by the end of 2014, and will use a Priority Review voucher for their alirocumab submission to FDA. Amgen announced today that it has submitted its PCSK9, evolocumab, to the European Medicines Agency—following its submission to FDA last week.

Merck announced today it will present detailed data on oncology drug pembrolizumab, the company's investigational anti-PD-1 antibody, on September 26-30 for the European Society of Medical Oncology Conference in Madrid. The drugmaker will unveil data for five solid-tumor types: advanced melanoma, no...

Read more

To category page

Loading...